INBX vs. CGON, FUSN, DNA, NVAX, SANA, BEAM, NMRA, ADMA, TARS, and KYMR
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include CG Oncology (CGON), Fusion Pharmaceuticals (FUSN), Ginkgo Bioworks (DNA), Novavax (NVAX), Sana Biotechnology (SANA), Beam Therapeutics (BEAM), Neumora Therapeutics (NMRA), ADMA Biologics (ADMA), Tarsus Pharmaceuticals (TARS), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
Inhibrx (NASDAQ:INBX) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.
In the previous week, CG Oncology had 7 more articles in the media than Inhibrx. MarketBeat recorded 8 mentions for CG Oncology and 1 mentions for Inhibrx. Inhibrx's average media sentiment score of 0.64 beat CG Oncology's score of 0.33 indicating that Inhibrx is being referred to more favorably in the media.
82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Inhibrx currently has a consensus target price of $27.00, suggesting a potential downside of 22.19%. CG Oncology has a consensus target price of $63.75, suggesting a potential upside of 112.64%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Inhibrx.
Inhibrx received 23 more outperform votes than CG Oncology when rated by MarketBeat users. However, 80.00% of users gave CG Oncology an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
CG Oncology has lower revenue, but higher earnings than Inhibrx.
CG Oncology has a net margin of 0.00% compared to Inhibrx's net margin of -13,408.95%. CG Oncology's return on equity of 0.00% beat Inhibrx's return on equity.
Summary
CG Oncology beats Inhibrx on 10 of the 15 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
